Last reviewed · How we verify
mycophénolate acid
At a glance
| Generic name | mycophénolate acid |
|---|---|
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors (PHASE4)
- Benefit of Immunoprophylaxis on Fibrosis to Reduce Viral Load After Liver Transplantation (PHASE4)
- Pharmacokinetic Evaluation of an Intensified and Decreasing Dosing Regimen of Mycophenolate Sodium in Combination With Tacrolimus Post Kidney Transplant: The Myfortic Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mycophénolate acid CI brief — competitive landscape report
- mycophénolate acid updates RSS · CI watch RSS
- Centre Hospitalier Universitaire de Saint Etienne portfolio CI